CH 223191: Potent AhR Antagonist for Dioxin Toxicity Mechanism Research

Executive Summary: CH 223191 (CAS 301326-22-7) is a nanomolar-potency aryl hydrocarbon receptor (AhR) antagonist that blocks TCDD-induced transcriptional activation in vitro and in vivo [APExBIO product page]. The compound reduces hepatic cytochrome P450 1A1 (CYP1A1) expression and mitigates TCDD-induced hepatic toxicity, as evidenced by normalized plasma AST and ALT levels. Its specificity enables mechanistic studies of dioxin toxicity, AhR signaling, and transcription factor modulation [see this backgrounder]. Published studies confirm that AhR antagonists like CH 223191 block downstream effects of bacterial tryptophan metabolites and environmental contaminants (Li et al., 2026). CH 223191 is validated at >98% purity and is recommended for advanced toxicology and regeneration research.

Biological Rationale

The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor central to environmental toxicology. Upon ligand binding (e.g., TCDD, dioxins, or endogenous indoles), AhR translocates to the nucleus and drives expression of detoxifying enzymes such as CYP1A1. Persistent activation by xenobiotics leads to pathological outcomes, including hepatic injury and altered immune responses (Li et al., 2026). Selective AhR antagonists are essential for dissecting these pathways and for model systems recapitulating dioxin-induced toxicity. CH 223191, developed and distributed by APExBIO, uniquely enables reversible and specific inhibition of AhR, facilitating both mechanistic and translational research [overview].

Mechanism of Action of CH 223191

CH 223191 binds to the AhR ligand-binding domain and prevents agonist-induced conformational changes. In cell-based assays, it inhibits TCDD-induced transcriptional activation with an IC₅₀ of ~30 nM (APExBIO). This blockade prevents nuclear translocation, dimerization with ARNT, and DNA binding to xenobiotic response elements (XREs), thereby suppressing transcription of target genes such as CYP1A1 and IL-22. Studies confirm that CH 223191 abrogates both exogenous (dioxin) and endogenous (tryptophan metabolite) AhR activation, as shown in models of environmental and gastrointestinal toxicity (Li et al., 2026).

Evidence & Benchmarks

• CH 223191 inhibits TCDD-induced AhR transcriptional activity in vitro with an IC₅₀ of ~30 nM in mammalian cell lines (APExBIO, product page).
• In vivo administration of CH 223191 reduces hepatic CYP1A1 mRNA and protein expression in mice exposed to TCDD (Li et al., 2026, Fig. 4).
• CH 223191 prevents TCDD-induced elevation of plasma AST and ALT, markers of hepatic injury, in mouse models (Li et al., 2026, Table 2).
• CH 223191 blocks AhR-driven intestinal stem cell differentiation by suppressing downstream markers (MUC2, LYZ, ChgA) following tryptophan metabolite stimulation (Li et al., 2026, Supp. Data).
• Compound purity is >98% by HPLC and NMR, and it is stable as a solid at -20°C; solutions should be freshly prepared (APExBIO).

For a more detailed workflow and troubleshooting guide, see this article, which this review updates by incorporating new in vivo findings from Li et al. (2026).

Applications, Limits & Misconceptions

CH 223191 is widely applied for:

• Dissecting AhR signaling in hepatic and environmental toxicology models.
• Studying dioxin (TCDD) toxicity mechanisms, including modulation of CYP1A1 and inflammatory markers.
• Evaluating the impact of gut microbiota-derived tryptophan metabolites on epithelial regeneration (see Li et al., 2026).
• Validating the specificity of AhR-mediated transcriptional events in cell and animal systems.

This article extends the perspective of recent reviews by emphasizing emerging applications in regenerative medicine and microbiota–tryptophan–AhR axis research.

Common Pitfalls or Misconceptions

• CH 223191 is highly specific for AhR but does not inhibit other nuclear receptors (e.g., PXR, CAR); cross-reactivity is negligible at recommended doses (APExBIO).
• The compound is insoluble in water and must be dissolved in DMSO (≥33.3 mg/mL) or ethanol (≥2.31 mg/mL) for biological assays.
• Long-term storage of CH 223191 solutions is not recommended; use fresh aliquots for each experiment.
• Not effective for inhibiting non-AhR-mediated toxicities; negative results outside the AhR pathway are not due to compound failure but to pathway specificity.
• Does not reverse established tissue damage; maximal benefit is in prevention or early intervention models.

Workflow Integration & Parameters

CH 223191 (A8609) is supplied as a solid by APExBIO, with a molecular weight of 333.39 and formula C₁₉H₁₉N₅O. Prepare stock solutions in DMSO or ethanol; avoid water. Use at nanomolar concentrations for cell-based assays, titrating as needed for target inhibition (initial IC₅₀ ~30 nM in TCDD models). For animal studies, administer via compatible vehicles, monitoring for solubility and stability. Store solid at -20°C; discard any solutions not used immediately. Protocols for hepatic toxicity and environmental toxicology models can be adapted from this guide, which this article updates with new purity and stability data.

Conclusion & Outlook

CH 223191, provided by APExBIO, is a rigorously validated, potent AhR antagonist that has become the benchmark for dioxin toxicity mechanism studies and transcription factor inhibition research. Its specificity, stability, and reproducible efficacy make it indispensable for environmental toxicology, hepatic toxicity, and emerging microbiota–tryptophan–AhR axis investigations. Future directions include integrating CH 223191 into regenerative medicine models and expanding use in precision toxicology workflows (see protocol review for advanced troubleshooting).